ArticleScientific reports2025
Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced inflammation via the 67LR/JAK2/STAT3 signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancing the frontiers of phytotherapy: a comprehensive review of botanical interventions targeting mitochondrial quality control to ameliorate endometriosis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Lipopolysaccharide (LPS) can trigger an inflammatory response in lung epithelial cells, which may contribute to the development of Acute Respiratory Distress Syndrome (ARDS). Epigallocatechin-3- gallate (EGCG), a bioactive constituent in green tea, is widely acknowledged for its anti-inflammatory characteristics. This study explored the anti-inflammatory effects of EGCG and its potential molecular mechanisms in mouse lung epithelial-12 (MLE-12) cells. MLE-12 cells were pre-exposed to increasing EGCG concentrations (5, 7.5, and 10 µM) for 24 h, followed by exposure to LPS (20 ng/mL) to induce inflammation After induction, cell and supernatant samples were collected. A range of detection methods were applied to systematically assess the anti-inflammatory activities and the latent mechanisms of EGCG, comprising real-time polymerase chain reaction assay (RT-PCR), enzyme-linked immunosorbent assays (ELISA), western blotting, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), transcriptome sequencing, immunofluorescence, co-immunoprecipitation, and confocal microscopy imaging. EGCG exhibited anti-inflammatory effects in LPS-stimulated MLE-12 cells by inhibiting the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Its primary mechanism involves robust attachment to 67-kDa laminin receptor (67LR), which modulates the interaction between 67LR and the JAK2 protein within the JAK2/STAT3 signaling pathway. This results in a considerable diminishment in LPS-induced production and expression of inflammatory-promoting cytokines in MLE-12 cells. EGCG attenuates the inflammatory reaction in MLE-12 cells by binding to 67LR and inhibiting the JAK2/STAT3 signaling pathway. The current study explored the effects of EGCG on LPS-induced inflammation in MLE-12 cells, which may offer some new perspectives in inflammation research and broadening our comprehension of the fundamental mechanisms inflammation-related diseases. Considering EGCG's role in suppressing inflammation in MLE-12 cells, it is reasonable to advocate, from a preventive perspective, the inclusion of EGCG-rich foods as a dietary component for helping alleviate the probability of inflammation-associated disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.